Nomura Holdings Inc. boosted its stake in I-Mab (NASDAQ:IMAB – Get Rating) by 0.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,613,214 shares of the company's stock after buying an additional 8,000 shares during the period. Nomura Holdings Inc. owned 3.14% of I-Mab worth $10,479,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of IMAB. Northwestern Mutual Wealth Management Co. acquired a new stake in I-Mab in the 2nd quarter valued at about $45,000. Acadian Asset Management LLC acquired a new stake in I-Mab in the 1st quarter valued at about $65,000. ExodusPoint Capital Management LP acquired a new stake in I-Mab in the 3rd quarter valued at about $42,000. OLD Mission Capital LLC acquired a new stake in I-Mab in the 3rd quarter valued at about $45,000. Finally, Virtus ETF Advisers LLC lifted its holdings in I-Mab by 265.0% in the 2nd quarter. Virtus ETF Advisers LLC now owns 11,446 shares of the company's stock valued at $129,000 after acquiring an additional 8,310 shares during the last quarter. Institutional investors own 37.02% of the company's stock.
Get I-Mab alerts:I-Mab Price Performance
Shares of NASDAQ IMAB opened at $3.70 on Friday. I-Mab has a twelve month low of $3.19 and a twelve month high of $21.44. The firm has a 50-day moving average of $5.29 and a two-hundred day moving average of $4.63.
I-Mab Profile
(Get Rating)
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial.
Featured Articles
- Get a free copy of the StockNews.com research report on I-Mab (IMAB)
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.